What is the Outcome in Patients with Acute Leukaemia who Survive Severe Acute Graft ‐versus‐Host Disease?

This study was a landmark analysis of 23,567 patients with acute Leukaemia who survived for more than 6 months after HSCT, 2002–2014. Patients alive after severe aGVHD (n = 1,738) were compared to controls. Patients with severe aGVHD had higher non‐relapse mortality (NRM) and higher rate of extensive chronic GVHD (cGVHD) than the controls (p < 10‐5). The probability of relapse was significantly lower in the severe aGVHD group, but Leukaemia‐free survival (LFS) and overall survival were significantly lower than for the controls (p < 10‐5). Five‐year LFS in patients with severe aGVHD was 49%, as opposed to 61% in controls with no or mild GVHD and 59% in patients with moderate GVHD. HSCT patients who survive severe aGVHD have higher risk of developing extensive cGVHD, a higher NRM, a lower relapse probability, and lower LFS than other HSCT patients. This study is a platform for outcome analysis in patients treated with novel therapies for acute GVHD.
This article is protected by copyright. All rights reserved.

Source: Journal of Internal Medicine - October 1, 2017 Category: Internal Medicine Authors: Olle Ringd én, Myriam Labopin, Behnam Sadeghi, Audrey Mailhol, Dietrich Beelen, Yngvar Fløisand, Ardeshir Ghavamzadeh, Jürgen Finke, Gerhard Ehninger, Liisa Volin, Gérard Socié, Nicolaus Kröger, Gernot Stuhler, Arnold Ganser, Christoph Schmid, Sebas Tags: Original Article Source Type: research